S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
Biden's Plan to Confiscate Your Cash? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Boredom, loneliness plague Ukrainian youth near front line
Norway hits export record amid soaring gas prices
US Dollar Replaced By "Biden Bucks"? (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
New climate deal spurs hopes of more carbon storage projects
US Dollar Replaced By "Biden Bucks"? (Ad)

Cue Biopharma - CUE Stock Forecast, Price & News

$3.34
-0.03 (-0.89%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.28
$3.42
50-Day Range
$2.45
$3.93
52-Week Range
$2.36
$18.42
Volume
101,773 shs
Average Volume
444,801 shs
Market Capitalization
$118.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.75

Cue Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
551.2% Upside
$21.75 Price Target
Short Interest
Healthy
6.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
1.88mentions of Cue Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$528,000 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.38) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

176th out of 1,125 stocks

Pharmaceutical Preparations Industry

74th out of 554 stocks

CUE stock logo

About Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Cue Biopharma Stock Performance

Shares of CUE Stock opened at $3.37 on Monday. Cue Biopharma has a fifty-two week low of $2.36 and a fifty-two week high of $18.42. The company has a debt-to-equity ratio of 0.17, a quick ratio of 8.29 and a current ratio of 8.29. The stock's 50-day simple moving average is $2.91 and its 200-day simple moving average is $4.29.

Cue Biopharma (NASDAQ:CUE - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.05. Cue Biopharma had a negative return on equity of 77.08% and a negative net margin of 418.33%. As a group, sell-side analysts forecast that Cue Biopharma will post -1.38 EPS for the current year.

Insider Activity at Cue Biopharma

In other news, Director Aaron G.L. Fletcher bought 150,000 shares of the company's stock in a transaction that occurred on Monday, May 23rd. The shares were purchased at an average price of $3.52 per share, for a total transaction of $528,000.00. Following the completion of the transaction, the director now directly owns 885,000 shares in the company, valued at $3,115,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 12.11% of the stock is owned by insiders.

Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Stock News Headlines

Cue Biopharma: A First Assessment
Cue Biopharma extends gains on insider purchase
See More Headlines
Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CUE
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.75
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+551.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-44,160,000.00
Net Margins
-418.33%
Pretax Margin
-414.09%

Debt

Sales & Book Value

Annual Sales
$14.94 million
Book Value
$2.06 per share

Miscellaneous

Free Float
31,097,000
Market Cap
$118.18 million
Optionable
Not Optionable
Beta
1.73

Key Executives














CUE Stock - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings
or view top-rated stocks.

What is Cue Biopharma's stock price forecast for 2022?

4 brokerages have issued 12-month price targets for Cue Biopharma's shares. Their CUE share price forecasts range from $15.00 to $26.00. On average, they anticipate the company's share price to reach $21.75 in the next year. This suggests a possible upside of 551.2% from the stock's current price.
View analysts price targets for CUE
or view top-rated stocks among Wall Street analysts.

How have CUE shares performed in 2022?

Cue Biopharma's stock was trading at $11.31 at the start of the year. Since then, CUE stock has decreased by 70.5% and is now trading at $3.34.
View the best growth stocks for 2022 here
.

When is Cue Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CUE earnings forecast
.

How were Cue Biopharma's earnings last quarter?

Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Cue Biopharma had a negative net margin of 418.33% and a negative trailing twelve-month return on equity of 77.08%.

What other stocks do shareholders of Cue Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include Prosight Management LP (4.68%), Sanders Morris Harris LLC (2.08%), Millennium Management LLC (1.70%), Renaissance Technologies LLC (1.64%), Monaco Asset Management SAM (1.25%) and P.A.W. Capital Corp (0.49%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Cameron Gray, Christopher A Marlett, Colin Sandercock, Daniel R Passeri, Kenneth Pienta and Kerri-Ann Millar.
View institutional ownership trends
.

How do I buy shares of Cue Biopharma?

Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $3.34.

How much money does Cue Biopharma make?

Cue Biopharma (NASDAQ:CUE) has a market capitalization of $118.18 million and generates $14.94 million in revenue each year.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.cuebiopharma.com. The company can be reached via phone at (617) 949-2680 or via email at ir@cuebio.com.

This page (NASDAQ:CUE) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.